Premium
A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers
Author(s) -
McMahon Lillian,
Tamary Hannah,
Askin Melissa,
AdamsGraves Patricia,
Eberhardt Robert T.,
Sutton Millicent,
Wright Elizabeth C.,
Castaneda Serguei A.,
Faller Douglas V.,
Perrine Susan P.
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08395.x
Subject(s) - medicine , refractory (planetary science) , randomized controlled trial , surgery , clinical trial , gastroenterology , arginine , butyrate , biochemistry , chemistry , physics , amino acid , astrobiology , food science , fermentation
Summary Sickle cell leg ulcers are often debilitating, refractory to healing, and prone to recurrence. Healing of leg ulcers was incidentally observed during dose‐ranging trials of Arginine Butyrate in beta haemoglobinopathies. Here, a controlled Phase II trial was performed in sickle cell patients who had lower extremity ulcers refractory to standard care for at least 6 months. Patients were randomized to receive standard local care alone (Control Arm) or standard care with Arginine Butyrate administered 5 d/week (Treatment Arm), for 12 weeks. Ulcers were photographed weekly, traced, and ulcer areas were calculated by computerized planimetry and compared between the two study arms. Twenty‐seven study courses were evaluated. Control Arm subjects had 25 ulcers with a mean area of 25·7 cm 2 initially and 23·2 cm 2 after 12 weeks; 2/25 (8%) healed completely. Treatment Arm subjects had 37 ulcers with a mean area of 50·6 cm 2 initially and 28·3 cm 2 at 12 weeks; 11/37 of these (30%) healed completely. After 3 months, proportions of ulcers which healed were 6/25 (24%) and 29/37 (78%), in the Control and Treatment Arms respectively ( P < 0·001). These findings strongly suggest that Arginine Butyrate merits further evaluation for the treatment of refractory sickle cell leg ulcers in larger trials.